Roland Chiu

Scientific Staff, Other Scientific Education Staff, Docent

University of Groningen
Country flagNetherlands

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Year:

2026

Introduction. Pseudoprogression (PsP) after proton therapy (PT) can mimic tumour progression and may cause neurological morbidity. We characterised PsP incidence, risk factors, spatial distribution and longitudinal dynamics in adults with IDH-mutated grade 2–3 glioma treated with PT.Methods. Patients treated between 2018–2022 were included. Post-PT MRIs were centrally reviewed for contrast-enhancing PsP. We estimated actuarial incidence (Kaplan–Meier), evaluated clinical risk factors using Cox regression, and analysed lesion location and volumetric behaviour over time.Results. PsP occurred in 33/137 (24.1%) patients; 8 (5.8%) developed symptomatic PsP (CTCAE grade ≥2). Mean time to first PsP was 18.1 months, and 2-year actuarial incidence was 18.1% overall (14.7% in grade 2 and 29.0% in grade 3 glioma). Independent risk factors were age >50 years (Hazard Ratio (HR) 2.5), Fazekas grade ≥2 on pre-PT MRI (HR 3.6), and treatment in 2021 (HR 3.2).In total, 115 PsP lesions were identified: 53 (46.1%) in the periventricular space (PVS) and 5 (4.3%) in the optic pathway. All symptomatic lesions involved the PVS and/or optic pathway. Symptomatic PVS-PsP showed multifocality, earlier onset (mean 14 months), faster growth (>0.5 cc/month) and larger cumulative volumes (>1.75 cc).Conclusion. Clinically consequential PsP after PT clustered in the PVS and optic pathway. Baseline clinical factors and simple volumetric dynamics may support risk-adapted surveillance and earlier multidisciplinary review, but proposed volumetric triggers require external validation.

Year:

2026

Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumour with limited treatment options and a poor prognosis. Therapeutic failure is driven by multiple barriers, including the blood–brain barrier (BBB), the tumour microenvironment (TME), and intratumoural heterogeneity. Conventional delivery systems often fail to achieve sufficient drug accumulation or controlled release within the tumour. In this review, we outline a theoretical framework for the design of ligand-functionalised magnetic lipid nanoparticles (MF-R-LNs), a multifunctional nanoplatform that integrates active targeting, stimuli-responsive drug release, and external magnetic-field control. The proposed MF-R-LNs incorporate superparamagnetic iron oxide nanoparticles (SPIONs) for magnetic guidance and hyperthermia; polyethylene glycol (PEG) for extended circulation; and surface ligands such as peptides, antibodies, or aptamers to target GBM-specific receptors including epidermal growth factor receptor (EGFR), Interleukin-13 receptor alpha-2 (IL-13Rα2), and integrins. Triggered release mechanisms such as pH-sensitive lipids, redox cleavable linkers, and enzyme-responsive coatings enable selective drug release within the TME. Magnetic hyperthermia serves as both a therapeutic modality and a remote trigger to enhance release and tumour penetration. This modular design offers a theoretically robust strategy to overcome the key physiological and therapeutic barriers in GBM. We discuss the rationale behind each design feature, explore potential synergies, and highlight translational challenges such as tumour heterogeneity, manufacturing complexity, and safety concerns. Despite encouraging preclinical evidence, clinical translation faces substantial hurdles, notably patient-specific heterogeneity and scalable GMP manufacturing/characterisation of multi-component nanoplatforms. While preclinical validation remains necessary, this framework may inform future efforts to develop spatiotemporally controlled, multifunctional therapeutics for glioblastoma. This manuscript is a conceptual framework review that synthesises current strategies into actionable guidance for designing and reporting MF-R-LNs for GBM.

Year:

2025

Collaborators (5)

Rob J.M. Groen

Professor in Clinical Neurosurgery

University Medical Center Groningen

NETHERLANDS
View details

Dirk Wagenaar

Medical Physicist

University Medical Center Groningen

NETHERLANDS
View details

Lara Barazzuol

Associate Professor

University Medical Center Groningen

NETHERLANDS
View details

Johannes A. Langendijk

Scientific Staff

University Medical Center Groningen

NETHERLANDS
View details

Steven Bergink

Scientific Staff, Other Scientific Education Staff, Docent

University of Groningen

NETHERLANDS
View details